GRI Bio (GRI Bio) Piotroski F-Score : N/A (As of Jun. 05, 2024)

View and export this data going back to 2023. Start your Free Trial

What is GRI Bio Piotroski F-Score?

The zones of discrimination were as such:

Good or high score = 7, 8, 9
Bad or low score = 0, 1, 2, 3

GRI Bio has an F-score of 3. It is a bad or low score, which usually implies poor business operation.

The historical rank and industry rank for GRI Bio's Piotroski F-Score or its related term are showing as below:

During the past 3 years, the highest Piotroski F-Score of GRI Bio was 3. The lowest was 3. And the median was 3.

GRI Bio Piotroski F-Score Historical Data

The historical data trend for GRI Bio's Piotroski F-Score can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

GRI Bio Piotroski F-Score Chart

GRI Bio Annual Data

Trend

Dec21

Dec22

Dec23

Piotroski F-Score

N/A

3.00

GRI Bio Quarterly Data
	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Piotroski F-Score	Get a 7-Day Free Trial					N/A	N/A	N/A	3.00	N/A

Competitive Comparison of GRI Bio's Piotroski F-Score

For the Biotechnology subindustry, GRI Bio's Piotroski F-Score, along with its competitors' market caps and Piotroski F-Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

GRI Bio's Piotroski F-Score Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, GRI Bio's Piotroski F-Score distribution charts can be found below:

* The bar in red indicates where GRI Bio's Piotroski F-Score falls into.

How is the Piotroski F-Score calculated?

This Year (Mar24) TTM:

Last Year (Mar23) TTM:

Net Income was -6.746 + -2.137 + -2.004 + -1.887 = $-12.77 Mil.
Cash Flow from Operations was -0.003 + -1.311 + -5.56 + -2.203 = $-9.08 Mil.
Revenue was 0 + 0 + 0 + 0 = $0.00 Mil.
Gross Profit was 0 + 0 + 0 + 0 = $0.00 Mil.
Average Total Assets from the begining of this year (Mar23)
to the end of this year (Mar24) was
(2.097 + 5.642 + 4.404 + 2.956 + 4.587) / 5 = $3.9372 Mil.
Total Assets at the begining of this year (Mar23) was $2.10 Mil.
Long-Term Debt & Capital Lease Obligation was $0.11 Mil.
Total Current Assets was $4.43 Mil.
Total Current Liabilities was $1.68 Mil.

Net Income was -0.295 + -0.351 + -2.269 + -2.15 = $-5.07 Mil.

Revenue was 0 + 0 + 0 + 0 = $0.00 Mil.
Gross Profit was 0 + 0 + 0 + 0 = $0.00 Mil.
Average Total Assets from the begining of last year (Mar22)
to the end of last year (Mar23) was
(0 + 0 + 0 + 0.383 + 2.097) / 5 = $1.24 Mil.
Total Assets at the begining of last year (Mar22) was $0.00 Mil.
Long-Term Debt & Capital Lease Obligation was $0.00 Mil.
Total Current Assets was $2.10 Mil.
Total Current Liabilities was $2.07 Mil.

*Note: If the latest quarterly/semi-annual/annual total assets data is 0, then we will use previous quarterly/semi-annual/annual data for all the items in the balance sheet.

Profitability

Question 1. Return on Assets (ROA)

Net income before extraordinary items for the year divided by Total Assets at the beginning of the year.

Score 1 if positive, 0 if negative.

GRI Bio's current Net Income (TTM) was -12.77. ==> Negative ==> Score 0.

Question 2. Cash Flow Return on Assets (CFROA)

Net cash flow from operating activities (operating cash flow) divided by Total Assets at the beginning of the year.

Score 1 if positive, 0 if negative.

GRI Bio's current Cash Flow from Operations (TTM) was -9.08. ==> Negative ==> Score 0.

Question 3. Change in Return on Assets

Compare this year's return on assets (1) to last year's return on assets.

Score 1 if it's higher, 0 if it's lower.

ROA (This Year)	=	Net Income	/	Total Assets (Mar23)
	=	-12.774	/	2.097
	=	-6.09155937

ROA (Last Year)	=	Net Income	/	Total Assets (Mar22)
	=	-5.065	/	0
	=

GRI Bio's return on assets of this year was -6.09155937. GRI Bio's return on assets of last year was . ==> This year is higher. ==> Score 1.

Question 4. Quality of Earnings (Accrual)

Compare Cash flow return on assets (2) to return on assets (1)

Score 1 if CFROA > ROA, 0 if CFROA <= ROA.

GRI Bio's current Net Income (TTM) was -12.77. GRI Bio's current Cash Flow from Operations (TTM) was -9.08. ==> -9.08 > -12.77 ==> CFROA > ROA ==> Score 1.

Funding

Question 5. Change in Gearing or Leverage

Compare this year's gearing (long-term debt divided by average total assets) to last year's gearing.

Score 0 if this year's gearing is higher, 1 otherwise.

Gearing (This Year: Mar24)	=	Long-Term Debt & Capital Lease Obligation	/	Average Total Assets from Mar23 to Mar24
	=	0.109	/	3.9372
	=	0.02768465

Gearing (Last Year: Mar23)	=	Long-Term Debt & Capital Lease Obligation	/	Average Total Assets from Mar22 to Mar23
	=	0	/	1.24
	=	0

GRI Bio's gearing of this year was 0.02768465. GRI Bio's gearing of last year was 0. ==> Last year is lower than this year ==> Score 0.

Question 6. Change in Working Capital (Liquidity)

Compare this year's current ratio (current assets divided by current liabilities) to last year's current ratio.

Score 1 if this year's current ratio is higher, 0 if it's lower

Current Ratio (This Year: Mar24)	=	Total Current Assets	/	Total Current Liabilities
	=	4.428	/	1.68
	=	2.63571429

Current Ratio (Last Year: Mar23)	=	Total Current Assets	/	Total Current Liabilities
	=	2.097	/	2.066
	=	1.01500484

GRI Bio's current ratio of this year was 2.63571429. GRI Bio's current ratio of last year was 1.01500484. ==> This year's current ratio is higher. ==> Score 1.

Question 7. Change in Shares in Issue

Compare the number of shares in issue this year, to the number in issue last year.

Score 0 if there is larger number of shares in issue this year, 1 otherwise.

GRI Bio's number of shares in issue this year was 3.196. GRI Bio's number of shares in issue last year was 0.422. ==> There is larger number of shares in issue this year. ==> Score 0.

Efficiency

Question 8. Change in Gross Margin

Compare this year's gross margin (Gross Profit divided by sales) to last year's.

Score 1 if this year's gross margin is higher, 0 if it's lower.

Gross Margin (This Year: TTM)	=	Gross Profit	/	Revenue
	=	0	/	0
	=

Gross Margin (Last Year: TTM)	=	Gross Profit	/	Revenue
	=	0	/	0
	=

GRI Bio's gross margin of this year was . GRI Bio's gross margin of last year was . ==> Last year's gross margin is higher ==> Score 0.

Question 9. Change in asset turnover

Compare this year's asset turnover (total sales for the year divided by total assets at the beginning of the year) to last year's asset turnover ratio.

Score 1 if this year's asset turnover ratio is higher, 0 if it's lower

Asset Turnover (This Year)	=	Revenue	/	Total Assets at the Beginning of This Year (Mar23)
	=	0	/	2.097
	=	0

Asset Turnover (Last Year)	=	Revenue	/	Total Assets at the Beginning of Last Year (Mar22)
	=	0	/	0
	=

GRI Bio's asset turnover of this year was 0. GRI Bio's asset turnover of last year was . ==> Last year's asset turnover is higher ==> Score 0.

Evaluation

Piotroski F-Score

Que. 1

Que. 2

Que. 3

Que. 4

Que. 5

Que. 6

Que. 7

Que. 8

Que. 9

Good or high score = 7, 8, 9
Bad or low score = 0, 1, 2, 3

GRI Bio has an F-score of 3. It is a bad or low score, which usually implies poor business operation.

GRI Bio (NAS:GRI) Piotroski F-Score Explanation

The developer of the system is Joseph D. Piotroski is relatively unknown accounting professor who shuns publicity and rarely gives interviews.

He graduated from the University of Illinois with a B.S. in accounting in 1989, received an M.B.A. from Indiana University in 1994. Five years later, in 1999, after earning a Ph.D. in accounting from the University of Michigan, he became an associate professor of accounting at the University of Chicago.

In 2000, he wrote a research paper called "Value Investing: The Use of Historical Financial Statement Information to Separate Winners from Losers" (pdf).

He wanted to see if he can develop a system (using a simple nine-point scoring system) that can increase the returns of a strategy of investing in low price to book (referred to in the paper as high book to market) value companies.

What he found was something that exceeded his most optimistic expectations.

Buying only those companies that scored highest (8 or 9) on his nine-point scale, or F-Score as he called it, over the 20 year period from 1976 to 1996 led to an average out-performance over the market of 13.4%.

Even more impressive were the results of a strategy of investing in the highest F-Score companies (8 or 9) and shorting companies with the lowest F-Score (0 or 1).

Over the same period from 1976 to 1996 (20 years) this strategy led to an average yearly return of 23%, substantially outperforming the average S&P 500 index return of 15.83% over the same period.

GRI Bio Piotroski F-Score Related Terms

Thank you for viewing the detailed overview of GRI Bio's Piotroski F-Score provided by GuruFocus.com. Please click on the following links to see related term pages.

GRI Bio (GRI Bio) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » GRI Bio Inc (NAS:GRI) » Definitions » Piotroski F-Score

Comparable Companies

Traded in Other Exchanges

N/A

Address

2223 Avenida De La Playa, Suite 208, La Jolla, CA, USA, 92037

Website

https://www.gribio.com

GRI Bio Inc is a clinical-stage biotech company focused on discovering, developing, and commercializing therapies targeting serious diseases associated with dysregulated immune responses that to inflammatory, fibrotic, and autoimmune disorders. GRI Bio's program, GRI-0621, is a small molecule RAR-beta and gamma dual agonist that inhibits the activity of human NKT I cells, returning the immune system to homeostasis.

Executives

David Leslie Szekeres	director	C/O REGULUS THERAPEUTICS INC., 3545 JOHN HOPKINS COURT, SUITE 210, SAN DIEGO CA 92121
Roelof Rongen	director	C/O MATINAS BIOPHARMA HOLDINGS, INC., 1545 ROUTE 206 SOUTH, SUITE 302, BEDMINSTER NJ 07921
Camilla V Simpson	director	20 ELAINE AVE., MILL VALLEY CA 94941
Albert Agro	officer: Chief Medical Officer	828 RICHMOND STREET WEST, TORONTO A6 M6J 1C9
Walter Marc Hertz	director, 10 percent owner, officer: Chief Executive Officer	2223 AVIENDA DE LA PLAYA, SUITE 208, LA JOLLA CA 92037
Vipin Chaturvedi	officer: Chief Scientific Officer	2223 AVIENDA DE LA PLAYA, SUITE 208, LA JOLLA CA 92037
Meenu Chhabra	director	C/O VALLON PHARAMCEUTICALS, INC., 100 N 18TH, STREET, SUITE 300, PHILADELPHIA PA 19103
Joseph E Payne	director	10628 SCIENCE CENTER DRIVE, SUITE 200, SAN DIEGO CA 92121
Leanne M. Kelly	officer: Chief Financial Officer	C/O VALLON PHARAMCEUTICALS, INC., 100 N 18TH STREET, SUITE 300, PHILADELPHIA PA 19103
Marella Thorell	director	1226 CHARTER LANE, AMBLER PA 19002
Arcturus Therapeutics Holdings Inc.	10 percent owner	10628 SCIENCE CENTER DRIVE, SUITE 250, SAN DIEGO CA 92121
Penny Toren	officer: SVP, Regul Affairs & Prog Mgmt	C/O VALLON PHARMACEUTICALS, INC., 100 N. 18TH STREET, SUITE 300, PHILADELPHIA PA 19103
Ofir Levi	director	C/O VALLON PHARMACEUTICALS, INC., 100 N. 18TH STREET, SUITE 300, PHILADELPHIA PA 19103
Richard Ammer	director, 10 percent owner	C/O VALLON PHARMACEUTICALS, INC., 100 N. 18TH STREET, SUITE 300, PHILADELPHIA PA 19103
Pharma Gmbh Salmon	10 percent owner	SANKT-JACOBS-STRASSE 90, CH-9002, BASEL V8 4052